Table 7.

The efficacy of the adefovir add-on treatment

	At 1 year (n = 36)	At 2 years (n = 19)	At 3 years (n = 11)
All patients (n = 36)
ALT Normalization	17 (47.2%)	11 (57.9%)	9 (81.8%)
Loss of HBV DNA	17 (47.2%)	13 (68.4%)	10 (90.9%)

	At 1 year (n = 25)	At 2 year (n = 13)	At 3 years (n = 8)
HBeAg-positive patients (n = 25)
ALT Normalization	12 (48.0%)	7 (53.8%)	7 (87.5%)
Loss of HBV DNA	9 (36.0%)	8 (61.5%)	7 (87.5%)
Loss of HBeAg	3 (12.0%)	5 (38.5%)	6 (75.0%)
HBeAg seroconversion	3 (12.0%)	5 (38.5%)	6 (75.0%)

	At 1 year (n = 11)	At 2 year (n = 6)	At 3 years (n = 3)
HBeAg-negative patients (n = 11)
ALT Normalization	5 (45.5%)	4 (66.7%)	2 (66.7%)
Loss of HBV DNA	8 (72.7%)	5 (83.3%)	3 (100%)

ALT: Alanine aminotransferase

HBeAg: Hepatitis B e antigen